Temozolomide

Temozolomide combined with radiation significantly improved overall survival in grade II glioma patients, with a hazard ratio of 0.54. Similar benefits were observed in patients with 1p/19q codeletions or astrocytoma. Temozolomide is considered a reasonable alternative to procarbazine, lomustine, and vincristine (PCV) until definitive results from a 2006-2007 randomized trial are available.

Vusolimogene oderparepvec (RP1) in combination with nivolumab received breakthrough therapy designation from the FDA for advanced melanoma. A biologics license application under the Accelerated Approval pathway has been filed. The treatment will undergo confirmatory analysis in the phase 3 IGNYTE-3 trial, which is currently enrolling patients with advanced melanoma who progressed on anti–PD-1 and anti–CTLA-4 therapy.

Novocure's new head flexible electrode (HFE) arrays for Optune Gio, a wearable treating glioblastoma, received FDA clearance. The HFEs are designed for comfort and will be transitioned to US users by mid-2025. Optune Gio uses 'tumour treating fields' (TTFields) alongside temozolomide chemotherapy to inhibit cancer cell growth.

FDA approves Novocure's new HFE transducer arrays for Optune Gio, designed to treat glioblastoma multiforme (GBM). The arrays are lighter, thinner, and aim to enhance patient comfort. Novocure plans to transition U.S. Optune Gio users to the new arrays by mid-2025.

Green Bay Packers QB Jordan Love wore a Brett Favre jersey to Lambeau Field, showing support after Favre's Parkinson's diagnosis. Favre, who suffered over 1,000 concussions, believes head trauma led to his condition. The NFL continues efforts to reduce concussion risks.

Amarex secures Orphan Drug Designation for Gibson Oncology's LMP744, a glioma treatment crossing the blood-brain barrier at 10x the concentration needed to kill cancer cells, targeting TOPO 1 and downregulating cMyc overexpression.

Adult IDH-wildtype glioblastoma patients provided informed consent for study, with prospective cohort (n=44) and retrospective cohort (n=18) analyzed. Tissue processing included dissociation, cell culture, and drug screening via PCY method. Key steps involved cell seeding, drug testing, immunocytochemistry, confocal microscopy, and PCY score calculation. Genetic alterations were determined via targeted next-generation sequencing, and scRNA-seq was used for single-cell transcriptome analysis. Additional techniques included siRNA knockdown, DRUG-seq, calcium assays, electrophysiology, and in vivo drug testing in mice.